COLUMBIA, SC/NOV 19, 2003 -- David J. Lewis, Chief Operating Officer, has been elected President & Chief Executive Officer of SleepMed incorporated effective January 1, 2004. He replaces Jerry K. Myers who was elected Vice Chairman.
Mr. Lewis joined Dr. Richard K. Bogan in 1994 to found Sleep Disorder Centers of America ("SDCA"), a sleep services company. As Chief Operating Officer of SDCA, he played a central role in its growth and its subsequent merger with DigiTrace Care Services, Inc. to form SleepMed. Mr. Lewis has served as Chief Operating Officer of SleepMed for the past four years. He is a 1988 graduate of the University of North Carolina at Chapel Hill with a degree in Health Policy Administration and earned his MBA and MHA from Georgia State University. Prior to SDCA and SleepMed, he held positions with T2 Medical, a home DME / home infusion company.
"I asked our Board of Directors to reduce my role at the Company so that I can devote more time to other activities," said Mr. Myers. "As Vice Chairman, I will continue to have an active role in the strategic direction of the business and I will stay in touch with day-to-day activities in the Company. I have a strong commitment to SleepMed and I will continue to devote a meaningful percentage of my time each year to Company business."
"It has been my privilege to serve as President & CEO of SleepMed since its formation in 1999," said Myers. "During that time, our employees have firmly established the Company as the leader in sleep services and expanded on our strong position in EEG. The opportunities for SleepMed today are even greater than they were four years ago. I have every confidence that David will provide the leadership to make SleepMed one of the premier companies in healthcare services."
SleepMed is the largest provider of diagnostic and treatment services for sleep and seizure disorders in the United States. Since its formation in 1999, SleepMed has tripled in size and has a presence in 39 states with over 100 sleep labs, 40 EEG testing sites, 70 hospital equipment accounts and three clinical research sites. The Company's proprietary DigiTrace monitoring system is the gold standard in ambulatory EEG and has been validated for unattended full PSG studies. The system has tested over 100,000 patients and has been used in national clinical drug studies for sleep and EEG.
Recently, SleepMed acquired the exclusive rights to Morpheus, a revolutionary software platform that provides a new approach to the scoring, networking and data management of sleep studies. The Company is developing a Morpheus-based sleep record outsourcing service that will be available to sleep labs and sleep centers throughout the country by early 2004.
